drugset / Trial / NCT02737072
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-09-25
- Completion
- 2017-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | LY2510924 | Peptide | 20 mg | Subcutaneous |
| Subject | LY2510924 | Peptide | 30 mg | Subcutaneous |
| Subject | LY2510924 | Peptide | 40 mg | Subcutaneous |